MedPath
HSA Product

POLARINE TABLET

Product approved by Health Sciences Authority (SG)

Basic Information

POLARINE TABLET

TABLET

Regulatory Information

SIN07612P

January 18, 1994

Pharmacy Only

Therapeutic

ORAL

August 10, 2023

May 30, 2025

XR06AB52

Company Information

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Active Ingredients

Detailed Information

Contraindications

**Contraindications:** This formula is contraindicated in patients exhibiting hypersensitivity to any of the components. Antihistamine are contraindicated in patients receiving monoamine oxidase inhibitors since these agents prolong and intensify the anticholinergic effects of anti-histamines. Antihistamines should not be used to treat lower respiratory tract symptoms. Sympathomimetic preparations are contraindicated in patients with severe hypertension, severe coronary artery disease and patients receiving MAO inhibitor therapy due to potentiation of the pressor effects of pseudoephedrine.

Indication Information

**Indications:** It is indicated in nasal and respiratory congestion, common cold, acute sinusitis, allergic rhinitis.

© Copyright 2025. All Rights Reserved by MedPath